Oxford Asset Management’s Champions Oncology CSBR Stock Holding History

Oxford Asset Management’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-21,075	Closed	-$165K	–	1710
2018 Q4	$165K	Buy	+21,075	New	+$242K	﹤0.01%	1581

Other funds holding CSBR

BPI

Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Oxford Asset Management's CSBR Position: Q1 2019 in Review

Oxford Asset Management sold out of Champions Oncology (CSBR) in Q1 2019, closing a stake of 21,075 shares — an estimated $165K sold.

Oxford Asset Management first reported a position in CSBR in Q4 2018 and held it in 1 quarter. The position peaked at $165K in Q4 2018. 38 funds tracked by Wall St. Rank hold CSBR as of Q1 2019.

Oxford Asset Management reported no remaining Champions Oncology position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 21,075 Champions Oncology shares in Q1 2019, an estimated $165K.
Oxford Asset Management first reported a position in Champions Oncology in Q4 2018 and held it in 1 quarter.
Oxford Asset Management's Champions Oncology position peaked at $165K in Q4 2018.
38 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.